2026 Annual Conference

Todd Bedrick has been at Absci for almost five years as its Chief Accounting Officer, supporting the company through its IPO and now as a clinical stage biotech. Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness.

Todd's prior experience include Ernst & Young and The Greenbrier Companies. Todd earned his BSBA in Accounting from the University of Arizona - Eller College of Management; he also holds an MS in Financial Analysis, received from Portland State University - School of Business.